Hemato Oncology Testing Market Size Worth US$ 5.6 Billion by 2027 | Growth Rate (CAGR) 14.2%
Hemato
Oncology Testing has become an essential part of the healthcare industry in
recent years. This form of testing is used to detect cancers in the blood and
bone marrow, as well as to monitor the progress of treatment for patients with
cancer. The global Hemato oncology testing market is projected to reach USD 5.6
billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 14.2%
The Hemato Oncology Testing market is driven by factors such
as the growing prevalence of cancer, technological advancements in diagnostic
testing, rising healthcare expenditure, and increasing awareness about early
diagnosis of cancer. Furthermore, the introduction of personalized medicine,
increasing use of companion diagnostics, and the development of novel therapies
have also contributed to the growth of the Hemato Oncology Testing market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877
The global Hemato Oncology Testing market is segmented by
test type, end user, and region. By test type, the Hemato Oncology Testing
market is divided into diagnostic testing, prognostic testing, and monitoring
testing. Diagnostic testing is further divided into flow cytometry, polymerase
chain reaction (PCR), cytogenetics, and immunohistochemistry. The end user
segment is divided into hospitals, diagnostic laboratories, and research
institutes.
Regionally, the Hemato Oncology Testing market is divided
into North America, Europe, the Asia Pacific, Latin America, and the Middle
East & Africa. North America is expected to dominate the global Hemato
Oncology Testing market due to the presence of a large number of diagnostic
laboratories and well-developed healthcare infrastructure in the region. Europe
is also expected to witness significant growth due to the increasing investment
in research and development activities. The Asia Pacific is also expected to
witness significant growth in the near future due to the increasing awareness
about early diagnosis of cancer and the presence of a large patient population
in the region.
Key Market Players
The market is competitive. The major players operating in
hemato oncology testing market are Abbott Laboratories (US), F. Hoffman-La
Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina
(US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP
Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies
(US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics
(Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink
(Sweden), Cancer Diagnostics (US).
Abbott Laboratories is the leading player in the
hemato-oncology testing market in 2021. In Abbott’s worldwide Diagnostics
business, sales increased by 42.7%. It offers kits for chronic lymphocytic
leukemia (CLL) and acute myeloid leukemia (AML). The company has been able to
introduce innovative products, such as Abbott RealTime IDH1 and Abbott RealTime
IDH2 assay kits, into the market. Abbott has a strong presence in the US, where
it registered USD 7,129 million the Diagnostics business. These players are
focusing on strategic initiatives such as collaborations, acquisitions, and product
launches to strengthen their positions in the market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877
This research report categorizes the hemato oncology
testing market based on Product and Services type, Cancer type, technology, and
region.
By Product & Service
- Services
- Assay
Kits
By Cancer Type
- Introduction
- Leukemia
- lymphoma
- Other cancers
By Technology
- Introduction
- PCR
- IHC
- NGS
- Cytogenetics
- Others
Technologies
by End User
- Introduction
- Clinical
laboratories
- Hospitals
- Academic
& Research Institutes
- Other
End Users
By Region
- Introduction
- North
America
- Europe
- Asia
Pacific
- Rest of
the World
Recent Developments:
- In 2022,
F. Hoffmann-La Roche Ltd. (Switzerland) received FDA approval for the
cobras EZH2 mutation test as a companion diagnostic for patients with
follicular lymphoma
- F.
Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) entered into a
15-year non-exclusive partnership with Illumina to broaden the adoption of
NGS-based testing in oncology.
- QIAGEN
N.V. (Germany) and Denovo Biopharma LLC (US) collaborated to develop a
blood-based companion diagnostic (CDx) test for treatment of diffuse large
B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
- Illumina,
Inc. (US) acquired GRAIL (US) QIAGEN collaborated with DeNovo to develop a
blood-based companion diagnostic (CDx) test for treatment of diffuse large
B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
- Thermo
Fisher Scientific Inc. (US) and First Genetics JCS (Russia) came into a
strategic partnership with First Genetics to focus on commercializing
NGS-based diagnostics in Russia.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine offering to drive
supernormal growth for progressive organizations in the B2B space. We have the
widest lens on emerging technologies, making us proficient in co-creating supernormal
growth for clients.
The B2B economy is witnessing the emergence of $25 trillion
of new revenue streams that are substituting existing revenue streams in this
decade alone. We work with clients on growth programs, helping them monetize
this $25 trillion opportunity through our service lines - TAM Expansion,
Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account
Enablement, and Thought Leadership Marketing.
Built on the 'Give Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive
ecosystem. Our insights and strategies are molded by our industry experts,
cutting-edge AI-powered Market Intelligence Cloud, and years of research. The
KnowledgeStore™ (our Market Intelligence Cloud) integrates our research,
facilitates an analysis of interconnections through a set of applications,
helping clients look at the entire ecosystem and understand the revenue shifts
happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow
us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Comments
Post a Comment